← All trials
NCT07279688
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2025
- Primary completion
- Nov 12, 2028
- Completion date
- Jun 12, 2029
- First posted
- Dec 12, 2025
- Last posted
- Dec 12, 2025
- Enrollment
- 140
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Western BrittanyLead sponsor
- Eli LillyCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.